So-called rare cancers, in one important respect, aren’t so rare at all. Diseases like retinoblastoma, Merkel cell carcinoma, and others actually account for 20 percent of all malignancies, and cause more deaths among younger people than the “big four” (lung, colon, breast, and prostate cancer).
But the patient groups are so fragmented, and the potential market for cures so thin, that researchers have little ability or incentive to attack these diseases, leaving patients with little hope or access to cutting-edge treatments.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
